Dayvigo (Lemborexant) Cost in Alabama 2026: Prices, Insurance, and Savings

What Does Dayvigo Actually Cost in Alabama?

The retail price of Dayvigo depends on whether you pay cash, use insurance, or access a savings program. Eisai lists Dayvigo at $320 per month for a 30-tablet supply of either the 5 mg or 10 mg strength, but very few patients pay this full amount out of pocket at Alabama pharmacies.

Average cash-pay prices across Alabama retail pharmacies sit around $85 per month in 2026. That figure reflects negotiated rates through discount programs like GoodRx and RxSaver, which aggregate pricing from chain and independent pharmacies statewide. The gap between $320 and $85 matters. It represents the difference between the wholesale acquisition cost (WAC) and the actual transaction price after pharmacy benefit manager (PBM) negotiations and cash-discount platforms take effect.

Prices vary by pharmacy. A Walgreens in Birmingham may quote a different cash price than an independent pharmacy in Mobile. Calling ahead or checking discount aggregators before filling is worth the two minutes it takes. The FDA-approved prescribing information for Dayvigo confirms that both the 5 mg and 10 mg tablets are available, and pricing at most Alabama pharmacies does not differ between the two strengths [1].

Lemborexant earned FDA approval in December 2019 as a dual orexin receptor antagonist (DORA) for insomnia characterized by difficulty with sleep onset and/or sleep maintenance. The SUNRISE-1 trial (N=1,006) demonstrated that lemborexant 5 mg and 10 mg both significantly reduced latency to persistent sleep (LPS) compared to placebo at 30 nights, with the 10 mg dose also outperforming zolpidem extended-release 6.25 mg on this measure [2]. That efficacy profile is what justifies the price point for many prescribers and patients weighing cost against clinical benefit.

Alabama Medicaid Does Not Cover Dayvigo

Alabama Medicaid's preferred drug list excludes Dayvigo as of 2026. Patients enrolled in Alabama Medicaid who need a DORA-class sleep medication face a coverage gap for this specific drug. No prior authorization pathway currently exists to obtain Medicaid coverage for lemborexant in the state.

This is not unusual. Many state Medicaid programs restrict newer branded insomnia medications in favor of generic alternatives like zolpidem, eszopiclone, or suvorexant (Belsomra, which lost patent exclusivity). Alabama Medicaid's formulary decisions are driven by the state's Drug Utilization Review (DUR) Board, which evaluates cost-effectiveness data alongside clinical evidence.

For Alabama Medicaid enrollees with insomnia, the practical options include generic zolpidem (typically under $15 per month), generic eszopiclone, or requesting a formulary exception if a clinician documents that the patient has failed or cannot tolerate formulary alternatives. The American Academy of Sleep Medicine's 2017 clinical practice guideline notes that orexin receptor antagonists represent a distinct mechanism from benzodiazepine receptor agonists, which may support exception requests when GABA-modulating agents have failed [3].

Dr. Andrew Krystal, a sleep researcher at UCSF who served as an investigator on multiple DORA trials, has noted: "The orexin antagonist mechanism offers a fundamentally different approach to treating insomnia compared to traditional hypnotics, particularly for patients with sleep maintenance difficulties." This distinction can form the clinical basis for a Medicaid exception appeal.

Which Commercial Insurance Plans Cover Dayvigo in Alabama?

Coverage for Dayvigo among Alabama commercial insurers varies by plan, but several of the state's largest carriers include it on their formularies with restrictions. Blue Cross Blue Shield of Alabama, the state's dominant commercial insurer, typically places Dayvigo on a specialty or non-preferred brand tier. This means a copay ranging from $50 to $150 per month depending on the specific plan design.

UnitedHealthcare and Aetna plans sold in Alabama also cover Dayvigo on higher formulary tiers. Prior authorization is standard across nearly all commercial payers. The typical PA criteria require documentation that the patient has tried and failed at least one generic sleep medication (usually zolpidem or eszopiclone) before Dayvigo will be approved.

Step therapy requirements add friction. A prescriber must document the failure of a first-line generic, specify the reason (lack of efficacy, adverse effects, or contraindication), and submit the PA request. Approval rates for Dayvigo PAs are generally favorable when step therapy criteria are met, but the process takes 3 to 14 business days depending on the payer.

The Endocrine Society's guidelines on sleep and metabolic health have documented the bidirectional relationship between insomnia and metabolic dysfunction, noting that "chronic sleep disruption increases insulin resistance and elevates cardiovascular risk markers" [4]. For patients with comorbid metabolic conditions, this evidence can strengthen a prior authorization by framing insomnia treatment as part of a broader metabolic health strategy.

Employer-sponsored plans through large Alabama employers (Regions Financial, Alabama Power, Huntsville Hospital) may have different formulary structures than individual marketplace plans. Checking the specific plan formulary through the insurer's member portal before the prescriber submits a PA saves time for everyone involved.

How the Eisai Savings Card Works for Alabama Patients

Eisai offers a manufacturer copay savings card for Dayvigo that can reduce out-of-pocket costs to as low as $0 for eligible commercially insured patients. The card covers up to a specified maximum annual benefit (currently around $3,600 per year) and is available to patients with commercial insurance who have a valid prescription.

Key eligibility rules apply. The savings card does not work for patients covered by Medicare, Medicaid, Tricare, or other government-funded insurance programs. Federal anti-kickback statutes prohibit manufacturer copay assistance for government-insured beneficiaries. Alabama patients on Medicare Part D who need Dayvigo must manage the Part D coverage gap (the "donut hole") without manufacturer support.

To activate the card, patients can enroll online through Eisai's DayvigoCopay program website or request a card through their prescriber's office. The card is presented at the pharmacy alongside the insurance card at the time of fill. The pharmacy processes both, and the savings card covers the difference between the insurance copay and the promotional price.

For uninsured Alabama patients paying cash, Eisai also offers a patient assistance program (PAP) that may provide Dayvigo at no cost to patients who meet income eligibility thresholds (typically below 400% of the federal poverty level). Application requires proof of income documentation and prescriber attestation. Processing takes approximately 4 to 6 weeks, so patients should plan ahead rather than expecting immediate access [1].

Compounded Lemborexant: Alabama Availability and Legality

Compounded lemborexant is available through licensed 503A compounding pharmacies in Alabama. Section 503A of the Federal Food, Drug, and Cosmetic Act permits state-licensed pharmacies to compound medications based on individual patient prescriptions from licensed prescribers.

The legality is straightforward. Alabama law follows federal 503A guidelines. A compounding pharmacy in Alabama with a valid state Board of Pharmacy license can compound lemborexant if it receives a patient-specific prescription, uses bulk drug substance from an FDA-registered supplier, and follows USP compounding standards (USP <795> for non-sterile preparations).

Cost is the primary draw. Compounded lemborexant may cost significantly less than the branded Dayvigo product at retail pharmacies. However, compounded products are not FDA-approved, do not undergo the same bioequivalence testing as commercial tablets, and may vary in formulation (capsule vs. tablet, different inactive ingredients).

The FDA's guidance on compounding emphasizes that "compounded drugs are not FDA-approved, which means they have not undergone FDA premarket review for safety, effectiveness, or quality" [5]. Patients considering compounded lemborexant should discuss this distinction with their prescriber.

Not every Alabama compounding pharmacy stocks lemborexant bulk powder. Patients in Birmingham, Huntsville, and Mobile have the most options. Rural areas may require mail-order compounding from an out-of-state 503A pharmacy that holds an Alabama non-resident pharmacy license, which is permitted under Alabama Board of Pharmacy rules.

Getting Dayvigo Through Telehealth in Alabama

Alabama permits telehealth prescribing of Dayvigo. Since lemborexant is a Schedule IV controlled substance (not Schedule II), Alabama's telehealth regulations allow a prescriber to evaluate a patient via synchronous audio-video visit and issue a prescription without a prior in-person exam.

The DEA's updated telemedicine prescribing rules that took effect in late 2025 extended the flexibilities for Schedule III through V controlled substances via telehealth, including lemborexant. Alabama adopted these federal allowances without additional state-level restrictions, making the prescribing pathway clean for both in-state and out-of-state telehealth providers licensed in Alabama [6].

Practical steps for Alabama patients: schedule a telehealth visit with a provider licensed in Alabama (either an Alabama-based practice or a multi-state telehealth platform), discuss your insomnia history and any prior medication trials, and if appropriate, the prescriber sends the Dayvigo prescription electronically to the Alabama pharmacy of your choice. The entire process, from scheduling to pharmacy fill, can take as little as 24 to 48 hours.

Telehealth visits for insomnia evaluation typically cost between $75 and $200 without insurance. Some platforms offer subscription models. HealthRX offers telehealth consultations for sleep-related prescriptions with board-certified providers licensed in Alabama.

How Dayvigo Compares to Other Sleep Medications on Cost

Putting Dayvigo's price in context against other insomnia medications available in Alabama helps frame the value calculation. Generic zolpidem (Ambien) costs $5 to $15 per month. Generic eszopiclone (Lunesta) runs $10 to $25 per month. Suvorexant (Belsomra), the first DORA approved in 2014, still costs around $400 per month at list price, though generic suvorexant became available in 2023 and now runs $30 to $60 per month in Alabama.

Dayvigo's $85 average cash price positions it between the cheapest generics and the most expensive branded options. For patients who have failed zolpidem or eszopiclone, the clinical rationale for a DORA-class agent is supported by mechanistic differences. DORAs block wakefulness-promoting orexin signaling rather than broadly enhancing GABAergic inhibition, which may produce a more physiologic sleep pattern with less next-day residual sedation.

The SUNRISE-2 trial (52 weeks, N=949) demonstrated sustained efficacy of lemborexant 5 mg and 10 mg on subjective sleep onset latency (sSOL) and subjective wake after sleep onset (sWASO) through 12 months, with no evidence of tolerance development [7]. This long-term data matters for cost calculations. A medication that maintains efficacy at a stable dose for a year costs less over time than one that requires dose escalation or switching.

The AASM's 2017 systematic review rated suvorexant (the DORA class representative available at that time) as effective for sleep maintenance insomnia with a "weak" recommendation strength, reflecting limited long-term data at the time of publication [3]. Lemborexant's longer-duration trials have since added to the DORA evidence base, though updated AASM guidelines incorporating lemborexant-specific data are still anticipated.

Tips for Reducing Your Dayvigo Costs in Alabama

A few concrete strategies can bring costs down. First, always check cash-discount platforms (GoodRx, RxSaver, SingleCare) before filling. Prices at Alabama pharmacies vary by $30 to $50 for the same medication depending on the pharmacy and the discount card used.

Second, ask your prescriber about the Eisai savings card at the time of prescribing. Activating the card before the first fill avoids paying a higher copay on the initial prescription and then applying the card retroactively (which is more paperwork).

Third, if your insurance denies coverage, request a formal appeal rather than accepting the denial. Include documentation of prior medication failures and relevant clinical trial data (SUNRISE-1, SUNRISE-2). Overturn rates on insomnia medication denials run approximately 40% to 60% on first appeal when proper documentation is submitted.

Fourth, consider a 90-day supply through mail-order pharmacy if your plan or discount program supports it. Mail-order pricing is typically 10% to 20% lower per unit than 30-day retail fills.

Fifth, for patients who are uninsured or underinsured, Eisai's patient assistance program and NeedyMeds (a nonprofit medication assistance database) can help identify programs specific to your situation. The NeedyMeds database tracks over 300 manufacturer assistance programs and is updated quarterly [8].